Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Thompson

Showing results (141-150 of 145) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 145 results.
MMWR. Morbidity and Mortality Weekly Report|March 31, 2022
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022Karthik Natarajan, Namrata Prasad, Kristin Dascomb, et al.
MMWR. Morbidity and Mortality Weekly Report|March 17, 2022
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022Ashley L Fowlkes, Sarang K Yoon, Karen Lutrick, et al.
MMWR. Morbidity and Mortality Weekly Report|November 4, 2021
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021Peter J Embi, Matthew E Levy, Allison L Naleway, et al.
JMIR Research Protocols|May 31, 2022
Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort StudyJoy Burns, Patrick Rivers, Lindsay B LeClair, et al.
The New England Journal of Medicine|June 30, 2021
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 VaccinesMark G Thompson, Jefferey L Burgess, Allison L Naleway, et al.
Pageof 15

Showing results (141-150 of 145) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 145 results.
MMWR. Morbidity and Mortality Weekly Report|March 31, 2022
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022Karthik Natarajan, Namrata Prasad, Kristin Dascomb, et al.
MMWR. Morbidity and Mortality Weekly Report|March 17, 2022
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022Ashley L Fowlkes, Sarang K Yoon, Karen Lutrick, et al.
MMWR. Morbidity and Mortality Weekly Report|November 4, 2021
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021Peter J Embi, Matthew E Levy, Allison L Naleway, et al.
JMIR Research Protocols|May 31, 2022
Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort StudyJoy Burns, Patrick Rivers, Lindsay B LeClair, et al.
The New England Journal of Medicine|June 30, 2021
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 VaccinesMark G Thompson, Jefferey L Burgess, Allison L Naleway, et al.
Pageof 15